BR112017003138A2 - anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno - Google Patents

anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno

Info

Publication number
BR112017003138A2
BR112017003138A2 BR112017003138A BR112017003138A BR112017003138A2 BR 112017003138 A2 BR112017003138 A2 BR 112017003138A2 BR 112017003138 A BR112017003138 A BR 112017003138A BR 112017003138 A BR112017003138 A BR 112017003138A BR 112017003138 A2 BR112017003138 A2 BR 112017003138A2
Authority
BR
Brazil
Prior art keywords
seq
hepatitis
antibodies
antigen binding
binding fragments
Prior art date
Application number
BR112017003138A
Other languages
English (en)
Inventor
Owsianka Ania
Patel Arvind
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of BR112017003138A2 publication Critical patent/BR112017003138A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

a invenção proporciona um anticorpo ou fragmento de ligação ao antígeno do mesmo capaz de se ligar à bolsa de ligação ao antígeno do anticorpo ap33, em que o referido anticorpo ou fragmento de ligação ao antígeno do mesmo compreende a cdr1 de vl (l1), a cdr2 de vl (l2), e a cdr3 de vl (l3) consistindo nas sequências de aminoácidos de seq id nº:1, seq id nº:2 e seq id nº:23, respectivamente, e compreende a cdr1 de vh (h1), a cdr2 de vh (h2), e a cdr3 de vh (h3) consistindo nas sequências de aminoácidos de seq id nº:24, seq id nº:25, e seq id nº:26, respectivamente. a invenção também proporciona composições, métodos, ácidos nucleicos e utilizações.
BR112017003138A 2014-09-05 2015-09-04 anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno BR112017003138A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1415714.3A GB201415714D0 (en) 2014-09-05 2014-09-05 Antibodies and antigen binding fragments thereof
PCT/GB2015/052558 WO2016034891A1 (en) 2014-09-05 2015-09-04 Anti-hepatitis c antibodies and antigen binding fragments thereof

Publications (1)

Publication Number Publication Date
BR112017003138A2 true BR112017003138A2 (pt) 2017-11-28

Family

ID=51796240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003138A BR112017003138A2 (pt) 2014-09-05 2015-09-04 anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno

Country Status (10)

Country Link
US (1) US10421805B2 (pt)
EP (1) EP3189076A1 (pt)
JP (1) JP6538151B2 (pt)
CN (1) CN107074964A (pt)
AU (1) AU2015310671B2 (pt)
BR (1) BR112017003138A2 (pt)
CA (1) CA2958030A1 (pt)
GB (1) GB201415714D0 (pt)
RU (1) RU2017111044A (pt)
WO (1) WO2016034891A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020124155A (ja) * 2019-02-05 2020-08-20 国立大学法人北陸先端科学技術大学院大学 タンパク質を生合成させる方法および未成熟終止コドンの修飾方法
CN116178536A (zh) * 2022-11-22 2023-05-30 上海交通大学医学院附属瑞金医院 小鼠抗人IV型胶原α5链NC1段单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433160T2 (de) * 1993-05-12 2004-07-08 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
CA2339045A1 (en) * 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
AU2006226192A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
US8603468B2 (en) * 2007-11-06 2013-12-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Neutralization of HCV
TW200940090A (en) * 2007-12-17 2009-10-01 Medical Res Council Technology Hepatitis C virus antibodies
US8858947B2 (en) * 2008-10-05 2014-10-14 The Board Of Trustees Of The Leland Stanford Junior University Hepatitis C antibodies and uses thereof
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv

Also Published As

Publication number Publication date
AU2015310671A1 (en) 2017-03-02
RU2017111044A3 (pt) 2018-10-05
JP6538151B2 (ja) 2019-07-03
US10421805B2 (en) 2019-09-24
GB201415714D0 (en) 2014-10-22
CN107074964A (zh) 2017-08-18
WO2016034891A1 (en) 2016-03-10
CA2958030A1 (en) 2016-03-10
EP3189076A1 (en) 2017-07-12
RU2017111044A (ru) 2018-10-05
AU2015310671B2 (en) 2019-01-03
JP2017527279A (ja) 2017-09-21
US20170283484A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
BR112019003775A2 (pt) anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
NZ773949A (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
PH12017500890A1 (en) Antibody drug conjugates
SG10201901057UA (en) Anti-pd-l1 antibodies
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
UA115781C2 (uk) Cx3cr1-зв'язуючий поліпептид
AR105267A1 (es) Anticuerpos de unión a tau
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
NZ728981A (en) Anti-ceramide antibodies
MY196874A (en) Humanized anti-basigin antibodies and the use thereof
WO2016112078A3 (en) Anti-phf-tau antibodies and their uses
NZ631473A (en) Anti-cd52 antibodies
BR112017003138A2 (pt) anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNITED KINGDOM RESEARCH AND INNOVATION (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements